Crossmark

What proportion of embryos should be considered for transfer following a mosaic diagnosis? A study of 115 clinics from a central diagnostic laboratory

Crossref DOI link: https://doi.org/10.1007/s10815-022-02678-8

Published Online: 2023-01-28

Published Print: 2023-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Sanders, Kathryn D. https://orcid.org/0000-0002-4774-5347
Griffin, Darren K. https://orcid.org/0000-0001-7595-3226
Martell, Henry J. https://orcid.org/0000-0002-7954-1672
Blazek, Joshua

Large, Michael https://orcid.org/0000-0002-0170-3918
Gordon, Tony https://orcid.org/0000-0003-2756-1943
Funding

Funding for this research was provided by:

CooperGenomics
License Information

Text and Data Mining valid from 2023-01-28

Version of Record valid from 2023-01-28
More Information

Article History

Received: 1 November 2021

Accepted: 2 December 2022

First Online: 28 January 2023

Declarations

:

: Tony Gordon is an employee and shareholder of CooperSurgical. Darren Griffin declares no conflict of interest but has been supported by CooperSurgical, Igenomix, London Women’s Clinic and CARE fertility. Kathryn Sanders was a PhD student supported by CooperSurgical and a shareholder of CooperSurgical. Joshua Blazek is an employee of CooperSurgical. Michael Large is an employee of CooperSurgical.

Document is current

Any future updates will be listed below